# US 2002/0177139 A1 · Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0177139 A1
- Document ID: US20020177139A1
- Status: Published application
- Kind: A1
- Application number: 09/997,169
- Filed: 2001-11-28
- Published: 2002-11-28
- Earliest claimed: 2000-11-28
- Assignees: Applera Corporation
- Inventors: Lawrence Greenfield; Luz Montesclaros
- Web page: https://patentgrep.com/patent/US20020177139A1

## CPC

- C12N 15/1006: {by means of a solid support carrier, e.g. particles, polymers}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to compositions and methods for isolating nucleic acids from biological samples, including whole tissue. The invention also provides kits for isolating nucleic acids from biological samples.

## Claims

### Claim 1

A method for obtaining nucleic acid from a biological sample and binding the nucleic acid to a solid phase, comprising:
contacting the biological sample with a disrupting buffer, wherein the disrupting buffer comprises:
a protease; and
a cationic surfactant;
substantially neutralizing the cationic surfactant; and
binding the nucleic acid to a solid phase.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cationic surfactant does not precipitate when the pH of the buffer is raised above pH 8.

### Claim 3 (depends on 1)

The method of claim 1, wherein the substantially neutralizing the cationic surfactant comprises removing the cationic surfactant.

### Claim 4 (depends on 1)

The method of claim 1, wherein the substantially neutralizing the cationic surfactant comprises adding a second surfactant that substantially neutralizes the cationic surfactant.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cationic surfactant is selected from at least one of the group comprising cetyltrimethylammonium bromide (CTAB), cetyltrimethylammonium chloride (CTACl), tetradecyltrimethylammonium bromide (TTAB), tetradecyltrimethylammonium chloride (TTACl), dodecyltrimethylammonium bromide (DTAB), dodecyltrimethylammonium chloride (DTACl), dodecylethyidimethylammonium bromide (DEDTAB), decyltrimethylammonium bromide (D10TAB), and dodecyltriphenylphosphonium bromide (DTPB).

### Claim 6 (depends on 4)

The method of claim 4, further comprising adding a salt.

### Claim 7 (depends on 6)

The method of claim 6, wherein the salt is selected from at least one of the group comprising NaBr, Nal, NaSCN, LiCI, LiBr, Lil, GUHCl, and GuSCN.

### Claim 8 (depends on 6)

The method of claim 6, wherein the salt is CaCl2 and is present in a concentration of at least 20 mM.

### Claim 9 (depends on 4)

The method of claim 4, wherein the second surfactant is a nonionic surfactant.

### Claim 10 (depends on 9)

The method of claim 9, wherein the nonionic surfactant is selected from at least one of the group comprising t-octylphenoxypolyethoxyethanol (Triton X-100), polyoxyethylenesorbitan monolaurate (Tween 21), polyoxyethylenesorbitan monopalmitate (Tween 40), polyoxyethylenesorbitan monostearate (Tween 60), polyoxyethylenesorbitan monooleate (Tween 80), polyoxyethylenesorbitan monotrioleate (Tween 85), (octylphenoxy)polyethoxyethanol (IGEPAL CA-630), triethyleneglycol monolauryl ether (Brij 30), and sorbitan monolaurate (Span 20).

### Claim 11 (depends on 9)

The method of claim 9, wherein the nonionic surfactant is polyoxyethylenesorbitan monolaurate (Tween 20).

### Claim 12 (depends on 11)

The method of claim 11, wherein the Tween 20 is present in a concentration of at least 4% w/w.

### Claim 13 (depends on 12)

The method of claim 12, wherein the Tween 20 is present in a concentration of 20% w/w.

### Claim 14 (depends on 1)

The method of claim 1, wherein the protease is selected from at least one of the group comprising subtilisins, subtilases, and alkaline serine proteases.

### Claim 15 (depends on 14)

The method of claim 14, wherein the protease is selected from at least one of the group comprising proteinase K, proteinase, R, proteinase T, subtilisin DY, an alkaline serine protease from Streptomyces griseus, an alkaline serine protease from Bacillus lichenformis, dispase, subtilisin Calsberg, subtilopeptidase A, and thermolysin.

### Claim 16 (depends on 1)

The method of claim 1, wherein the protease is a thermostable protease.

### Claim 17 (depends on 16)

The method of claim 16, wherein the thermostable protease is isolated from an organism selected from at least one of the group comprising Thermus Rt41A and Bacillus thermoproteolyticus rokko.

### Claim 18 (depends on 4)

The method of claim 4, wherein the disrupting buffer further comprises a ribonuclease inhibitor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the ribonuclease inhibitor is selected from at least one of the group comprising vanadylate ribonucleoside complexes, phenylglyoxal, p-hydroxyphenylglyoxal, polyamines, spermidine, 9-aminoacridine, iodoacetate, bentonite, poly[2′-O-(2,4-dinitrophenyl)]poly(adenyhlic acid), zinc sulfate, bromopyruvate, formamide, copper, and zinc.

### Claim 20 (depends on 18)

The method of claim 18, wherein the ribonuclease inhibitor is aurintricarboxylic acid.

### Claim 21 (depends on 20)

The method of claim 20, wherein the aurintricarboxylic acid is present in a concentration of 10 μM.

### Claim 22 (depends on 4)

The method of claim 4, further comprising adding a deoxyribonuclease inhibitor.

### Claim 23 (depends on 22)

The method of claim 22, wherein the deoxyribonuclease inhibitor comprises a divalent cation chelator.

### Claim 24 (depends on 23)

The method of claim 23, wherein the divalent cation chelator is selected from at least one of the group comprising EDTA, EGTA, and DPTA.

### Claim 25

A method for obtaining nucleic acid from a biological sample and binding the nucleic acid to a solid phase, comprising:
contacting the biological sample with a disrupting buffer, wherein the disrupting buffer comprises:
a protease; and
a cationic surfactant; and
binding the nucleic acid to a solid phase.

### Claim 26 (depends on 25)

The method of claim 25, wherein the cationic surfactant is selected from at least one of the group comprising cetyltrimethylammonium bromide (CTAB), cetyltrimethylammonium chloride (CTACl), tetradecyltrimethylammonium bromide (TTAB), tetradecyltrimethylammonium chloride (TTACl), dodecyltrimethylammonium bromide (DTAB), dodecyltrimethylammonium chloride (DTACl), dodecylethyldimethylammonium bromide (DEDTAB), decyltrimethylammonium bromide (D10TAB), and dodecyltriphenylphosphonium bromide (DTPB).

### Claim 27 (depends on 25)

The method of claim 25, further comprising adding a salt.

### Claim 28 (depends on 27)

The method of claim 27, wherein the salt is selected from at least one of the group comprising NaBr, Nal, NaSCN, LiCl, LiBr, Lil, GUHCl, and GuSCN.

### Claim 29 (depends on 27)

The method of claim 27, wherein the salt is CaCl2 and is present in a concentration of at least 20 mM.

### Claim 30 (depends on 25)

The method of claim 25, wherein the protease is selected from at least one of the group comprising subtilisins, subtilases, and alkaline serine proteases.

### Claim 31 (depends on 30)

The method of claim 30, wherein the protease is selected from at least one of the group comprising proteinase K, proteinase, R, proteinase T, subtilisin DY, an alkaline serine protease from Streptomyces griseusa, an alkaline serine protease from Bacillus lichenformis, dispase, subtilisin Calsberg, subtilopeptidase A, and thermolysin.

### Claim 32 (depends on 25)

The method of claim 25, wherein the protease is a thermostable protease.

### Claim 33 (depends on 32)

The method of claim 32, wherein the thermostable protease is isolated from an organism selected from at least one of the group comprising Thermus Rt41A and Bacillus thermoproteolyticus rokko.

### Claim 34 (depends on 25)

The method of claim 25, wherein the disrupting buffer further comprises a ribonuclease inhibitor.

### Claim 35 (depends on 34)

The method of claim 34, wherein the ribonuclease inhibitor is selected from at least one of the group comprising vanadylate ribonucleoside complexes, phenylglyoxal, p-hydroxyphenylglyoxal, polyamines, spermidine, 9-aminoacridine, iodoacetate, bentonite, poly[2′-O-(2,4-dinitrophenyl)]poly(adenyhlic acid), zinc sulfate, bromopyruvate, formamide, copper, and zinc.

### Claim 36 (depends on 34)

The method of claim 34, wherein the ribonuclease inhibitor is aurintricarboxylic acid.

### Claim 37 (depends on 36)

The method of claim 36, wherein the aurintricarboxylic acid is present in a concentration of 10 μM.

### Claim 38 (depends on 25)

The method of claim 25, further comprising adding a deoxyribonuclease inhibitor.

### Claim 39 (depends on 38)

The method of claim 38, wherein the deoxyribonuclease inhibitor comprises a divalent cation chelator.

### Claim 40 (depends on 39)

The method of claim 39, wherein the divalent cation chelator is selected from at least one of the group comprising EDTA, EGTA, and DPTA.

### Claim 41

A kit comprising:
a protease;
a cationic surfactant; and
a second surfactant, wherein the second surfactant substantially neutralizes the cationic surfactant.

### Claim 42 (depends on 41)

The kit of claim 41, wherein the cationic surfactant does not precipitate when the pH of the buffer is raised above pH 8.

### Claim 43 (depends on 41)

The kit of claim 41, wherein the cationic surfactant is selected from at least one of the group comprising cetyltrimethylammonium bromide (CTAB), cetyltrimethylammonium chloride (CTACl), tetradecyltrimethylammonium bromide (TTAB), tetradecyltrimethylammonium chloride (TTACl), dodecyltrimethylammonium bromide (DTAB), dodecyltrimethylammonium chloride (DTACl), dodecylethyidimethylammonium bromide (DEDTAB), decyltrimethylammonium bromide (D10TAB), and dodecyltriphenylphosphonium bromide (DTPB).

### Claim 44 (depends on 41)

The kit of claim 41, wherein the protease is selected from at least one of the group comprising subtilisins, subtilases, and alkaline serine proteases.

### Claim 45 (depends on 44)

The kit of claim 44, wherein the protease is selected from at least one of the group comprising proteinase K, proteinase, R, proteinase T, subtilisin DY, an alkaline serine protease from Streptomyces griseus, an alkaline serine protease from Bacillus lichenformis, dispase, subtilisin Calsberg, subtilopeptidase A, and thermolysin.

### Claim 46 (depends on 41)

The kit of claim 41, wherein the protease is a thermostable protease.

### Claim 47 (depends on 46)

The kit of claim 46, wherein the thermostable protease is isolated from an organism selected from at least one of the group comprising Thermus Rt41A and Bacillus thermoproteolyticus rokko.

### Claim 48 (depends on 41)

The kit of claim 41, wherein the kit further comprises a ribonuclease inhibitor.

### Claim 49 (depends on 48)

The kit of claim 48, wherein the ribonuclease inhibitor is selected from at least one of the group comprising vanadylate ribonucleoside complexes, phenylglyoxal, p-hydroxyphenylglyoxal, polyamines, spermidine, 9-aminoacridine, iodoacetate, bentonite, poly[2′-O-(2,4-dinitrophenyl)]poly(adenyhlic acid), zinc sulfate, bromopyruvate, formamide, copper, and zinc.

### Claim 50 (depends on 48)

The kit of claim 48, wherein the ribonuclease inhibitor is aurintricarboxylic acid.

### Claim 51 (depends on 50)

The kit of claim 50, wherein the aurintricarboxylic acid is present in a concentration of 10 μM.

### Claim 52 (depends on 41)

The kit of claim 41, wherein the kit further comprises a deoxyribonuclease inhibitor.

### Claim 53 (depends on 52)

The kit of claim 52, wherein the deoxyribonuclease inhibitor comprises a divalent cation chelator.

### Claim 54 (depends on 53)

The kit of claim 53, the divalent cation chelator is selected from at least one of the group comprising EDTA, EGTA, and DPTA.

### Claim 55 (depends on 41)

The kit of claim 41, further comprising a salt.

### Claim 56 (depends on 55)

The kit of claim 55, wherein the salt is selected from the group comprising NaBr, Nal, NaSCN, LiCI, LiBr, Lil, GuHCl, and GuSCN.

### Claim 57 (depends on 55)

The kit of claim 55, wherein the salt is CaCl2.

### Claim 58 (depends on 57)

The kit of claim 57, wherein the CaCl2 is present in a concentration of at least 20 mM.

### Claim 59 (depends on 41)

The kit of claim 41, wherein the second surfactant is a nonionic surfactant.

### Claim 60 (depends on 59)

The kit of claim 59, wherein the nonionic surfactant is selected from the group comprising t-octylphenoxypolyethoxyethanol (Triton X-100), polyoxyethylenesorbitan monolaurate (Tween 21), polyoxyethylenesorbitan monopalmitate (Tween 40), polyoxyethylenesorbitan monostearate (Tween 60), polyoxyethylenesorbitan monooleate (Tween 80), polyoxyethylenesorbitan monotrioleate (Tween 85), (octylphenoxy)polyethoxyethanol (IGEPAL CA-630), triethyleneglycol monolauryl ether (Brij 30), and sorbitan monolaurate (Span 20).

### Claim 61 (depends on 59)

The kit of claim 59, wherein the nonionic surfactant is polyoxyethylenesorbitan monolaurate (Tween 20).

### Claim 62 (depends on 61)

The kit of claim 61, wherein the Tween 20 is present in a concentration of at least 4% w/w.

### Claim 63 (depends on 61)

The kit of claim 61, wherein the Tween 20 is present in a concentration of 20% w/w.

### Claim 64

A kit for obtaining nucleic acid from a biological sample comprising:
a protease;
a cationic surfactant;
a non-ionic surfactant, wherein the non-ionic surfactant permits the binding of nucleic acid to a solid phase in the presence of the protease and cationic surfactant; and
a buffer with a high salt concentration.
